Ashvin Bashyam

[Ashvin Bashyam @Ashviin]

I am thrilled to share the unveiling of @ensomabio, the latest company to launch from @5AMVentures! We're bringing the curative power of genomic medicines to patients with a next-generation, fully in vivo approach. Check out our website to learn more https://t.co/edP54Ri7Gp

[Gleb Kuznetsov @glebkuz]

What you’re seeing at @ManifoldBio is what happens when two exponentials begin to resonate–the evolution of AI and the evolution of massively parallel molecular measurement and design.

When we started Manifold Bio with @PierceOgdenJ , @geochurch , and @slofgren, we set out to do something bold: to build an AI-first biopharma company that could map the astronomic space of molecular design against the complexity of human biology.

We had already become world leaders in the secret art of combining Machine Learning and Multiplexed Libraries, or ML². We believed this approach could be transformative to drug discovery.

AI in drug discovery has always faced one fundamental barrier: the translational gap between what works in a petri dish and what will work in a patient. We believed that closing that gap required a way to power AI models with massive-scale experimental feedback directly from living organisms.

Such a platform would be positioned to solve grand challenges in human health, including creating medicines that could cross the blood-brain barrier.

To succeed in such a challenge, it not only takes a culture of scientific boldness, but also bold partners. The boldness of the Roche team was clear from the moment we started mapping out this collaboration, both in their rigor in evaluation of the Manifold platform and the ambition we both shared in how to best leverage our approach. This is the company that has literally integrated the Genentech DNA, and charted many firsts along the way, including some of the most compelling brain-shuttling clinical data to date. It’s a privilege to combine forces to advance the frontier of brain delivery together.

This deal is fantastic validation of the power of our approach. And we’re just getting started.

[Eric Vallabh Minikel @cureffi]

I've finally digested the data that Uniqure presented on AMT-130, their gene therapy for Huntington's disease, which just announced a positive trial readout with 75% slowing of disease progression. Here is a blog post with my take on the announcement: https://t.co/7Rz1hGQ0X2

[Lexi Rovner @lexrovner]

I’m really excited to see what happens at the interface of biotech and AI over the next few years. The scale and type of data generation will be key. Gleb & crew have been building something really unique and special here. Give it a read: @glebkuz @PierceOgdenJ @slofgren

[Ethan J. Weiss @ethanjweiss]

Charles did not have a roadmap for what he envisioned but he did have two guiding principles:

1. Do something important. That is, work to develop new medicines that would address important areas of biology or medicine.

2. Do something different. Again, these cannot be exclusive. I.e., don't be different and not important. But Charles guided us to aspire to be creative in trying to find areas of biology and medicine that were not well-addressed or were not likely to be addressed soon.

[Minhua Chu @chuminhua432]

🇨🇳 #AusperBio announced the presentation of end-of-treatment (EOT) clinical data from its ongoing Phase IIb trial of AHB-137 in a late-breaking poster session #easl2025 https://t.co/nwcLe57kHa

AHB-137 is an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B virus (HBV) infection for functional cure.

16 or 24 weeks of AHB-137 treatment.
The primary endpoint, HBsAg < 0.05 IU/mL, the lower limit of quantification (LLOQ), and HBV DNA < LLOQ (10 IU/mL) at the end of treatment,
was achieved by 66% (21/32) in the 16-week arm and 75% (24/32) in the 24-week arm.

Among patients achieving the primary endpoint, >80% experienced HBsAg loss within 12 weeks, and anti-HBs seroconversion at the end of treatment was observed in 33% and 54% of subjects in the 16-week and 24-week arms, respectively.

[Mikhail Shapiro (same on bsky) @mikhailshapiro]

A big step forward for biomolecular ultrasound! 🔊
Congrats @bgheiles, @DMarescalab at @tudelft and collaborators! #gasvesicles

[Harry McNamara @h4rrymcnamara]

a personal update: in January, I'm moving to Yale to join @MCDB_Yale and to open my lab in the @WuTsaiYale Institute!

We will investigate multicellular self-organization using synbio tools to read and write developmental signals in stem cell models.

https://t.co/RIe5kwbg1W

[Andrew Warren @SurelyAndrew]

I am $30 away from $10,000 raised for cancer research through the Damon Runyon Cancer Research Foundation!

To celebrate, here’s the board game @Heleninthecloud and I made! We just got the alpha copies in the mail earlier this week and they look amazing!!

[Arnav Mehta @arnavmehta3]

Beautiful work by ⁦@omarabudayyeh⁩ and ⁦@jgooten⁩ demonstrating rapid optimization of protein fitness / activity with assisted directed evolution https://t.co/1BTf7hm6cy

[Andrew Warren @SurelyAndrew]

Something new is in the cards…help me fundraise $50,000 for the Damon Runyon Cancer Research Foundation as part of the @ldtimmerman Traverse to Everest Base Camp!

If you are board this weekend, check out the new game @Heleninthecloud and I are creating to support the fundraise!

[Daniel Bryan Goodman @dbgoodman]

Big news! 🥳🥂 In July 2025, I will be joining the faculty of University of Pennsylvania, @Penn_CBIO. The Goodman Lab for Synthetic Immunology will combine synthetic biology, genome engineering, and ML-driven functional genomics to study and manipulate primary immune cells. 🧵1/3

[Dan Roberts @danintheory]

I guess machine learning is actually physics after all…

[Dan Roberts @danintheory]

Do LLMs really need to be so L?

That's a rejected title for a new paper w/ @Andr3yGR, @kushal_tirumala, @Hasan_Shap, @PaoloGlorioso1 on pruning open-weight LLMs: we can remove up to *half* the layers of Llama-2 70B w/ essentially no impact on performance on QA benchmarks.

1/

[Luke Timmerman @ldtimmerman]

Terrific way to start #JPM24. 2nd annual Timmerman Traverse alumni hike. Thanks Jen McNealey, TT for LSC '22 alum, for organizing. Conversations about biotech, nature, exploring, and giving back. @LS_Cares @DamonRunyon @fredhutch

[Dan Roberts @danintheory]

Extreme scenarios of AI focus on what is logically possible rather than what is physically possible.

What does physics have to say about AI risk?

1/2

[Elicit @elicitorg]

1/ Announcing our spinoff from @oughtinc into a public benefit corporation, our $9 million seed round, and a much more powerful Elicit!

This new Elicit takes the components of the popular literature review workflow and extends them to automate more research workflows.

[Luke Timmerman @ldtimmerman]

From Structural Biology to Structuring Companies. Deb Palestrant of 5AM Ventures is the latest guest on The Long Run podcast. @debpalestrant @5amVentures https://t.co/SQv7yasjBr

[Ensoma @EnsomaBio]

We're pleased to announce the closing of a $135M financing round including a Series B extension of $50M. These funds will be used to advance the development of our in vivo engineered cell therapy platform &amp; pipeline of genomic medicines. Learn more: https://t.co/8YunQbNz2X

[Luke Timmerman @ldtimmerman]

Gene editing therapies delivered in vivo. Ensoma CEO Emile Nuwaysir is the latest guest on The Long Run. https://t.co/Daicu6HuQu

[Luke Timmerman @ldtimmerman]

The biotech community is coming together to fight poverty. Timmerman Traverse for @LS_Cares raised more than $100,000 this week. Find a hiker you know on the team page, and show us your support. 👇https://t.co/Fhb7BdpkwS